The Food and Drug Administration has approved a new oral medication, Lipfendra, designed to significantly reduce high cholesterol levels in patients for whom standard statin treatments are insufficient. This marks a significant development as it is the first non-injectable drug of its kind to target the PCSK9 protein.
Developed by Merck, Lipfendra is indicated for patients with artery-clogging cholesterol that persists even after they have taken statins, the common first-line medication for reducing heart attack risk. For over a decade, injectable drugs targeting the PCSK9 protein have been available, but have faced challenges related to high costs, insurance restrictions, and limited physician prescribing.
The PCSK9 protein plays a role in the body's ability to clear cholesterol from the blood. By blocking this protein, Lipfendra aims to enhance cholesterol removal. Statins, which are the cornerstone of cholesterol management, work by reducing the liver's cholesterol production. However, for many patients, even maximum doses of statins do not lower low-density lipoprotein (LDL) cholesterol to recommended guideline levels.
Merck's approval was based on two clinical trials involving high-risk patients who added Lipfendra to their existing treatment regimens, which included statins. In one study with 3,000 participants, those taking Lipfendra experienced an LDL cholesterol reduction of over 55% after six months. A second study showed an average reduction of 59% compared to a placebo group.
Researchers noted that the benefits of the drug were sustained with only a minor decrease over a year. The side effects observed, such as dizziness and diarrhea, were comparable between the group taking Lipfendra and the placebo group. A key administration note is that the pill must be taken on an empty stomach.
The FDA granted this drug expedited review under a program for promising medications that address public health needs. High LDL cholesterol is a primary risk factor for heart attacks and strokes, which are the leading causes of death in the United States. While an LDL level of 100 mg/dL is considered acceptable for healthy individuals, medical guidelines recommend levels of 70 mg/dL or lower for those with high cholesterol or existing heart disease, and even lower for very high-risk individuals.